Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study

Masaki Kanazu1, Masahide Mori1, Madoka Kimura2, Kazumi Nishino2, Takayuki Shiroyama3, Izumi Nagatomo3, Shoichi Ihara4, Kiyoshi Komuta5, Hidekazu Suzuki6, Tomonori Hirashima6, Toru Kumagai2 & Fumio Imamura2

1 Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Japan
2 Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan
3 Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan
4 Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan
5 Department of Respiratory Medicine, Daini Osaka Police Hospital, Osaka, Japan
6 Department of Thoracic Oncology, Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, Habikino, Japan

Keywords
Afatinib; epidermal growth factor receptor; erlotinib; gefitinib; uncommon mutation.

Abstract
Background: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy is the standard treatment for advanced non-small cell lung cancer (NSCLC) harboring common EGFR mutations, such as exon 19 deletion or L858 point mutation. However, the effectiveness of EGFR-TKIs for patients with uncommon EGFR mutations remains unclear.

Methods: We retrospectively surveyed a consecutive database of NSCLC patients with EGFR mutations at five participating institutions. Data from NSCLC patients with uncommon mutations (including single or compound mutations), who were treated with systemic therapy between May 2016 and October 2018, were collected and analyzed.

Results: A total of 23 of the 524 patients whose data were collected had uncommon EGFR mutations. Of these, 22 received EGFR-TKIs (gefitinib = 6, erlotinib = 4, and afatinib = 12). Patients who received first EGFR-TKIs had overall response and disease control rates of 59.1% and 81.8%, respectively. The median progression-free survival (PFS) of patients with G719X mutation (n = 13, median PFS = 32.9 months) was favorable, compared with those of patients with L861Q mutation (n = 4, median PFS = 6.4 months) and compound mutations (n = 4, median PFS = 7.3 months). The PFS of patients who received first- and second-generation EGFR-TKIs was 14.0 months (n = 10) and 7.3 months (n = 12), respectively. The median cumulative duration of treatment (DOT) with EGFR-TKIs was 30.4 months, which was longer than those of cytotoxic chemotherapy (median DOT = 10.7 months) or immune checkpoint inhibitors (median DOT = 6.6 months).

Conclusions: EGFR-TKIs elicit favorable responses and contribute to long-term disease control in NSCLC patients with uncommon EGFR mutations.

Key points
Significant findings of the study
Our results demonstrate that both first- and second-generation EGFR-TKIs elicit favorable responses in NSCLC patients with uncommon EGFR mutations.
What this study adds
This study revealed all clinical courses for NSCLC patients with uncommon EGFR mutations. In addition to EGFR-TKIs, CCT and ICIs were found to contribute to long-term disease control in this cohort.

Introduction
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been reported to induce a dramatic response in tumors harboring activating EGFR mutations. Two major types of EGFR mutations, in-frame deletional mutation in exon 19 and L858R point mutation in exon 21, have been confirmed to confer sensitivity to EGFR-TKIs.1–5 Other mutations, such as amino acid substitutions in G719, S768, and L861, constitute approximately 10% of all EGFR mutations.6–9 Although preclinical models demonstrate that uncommon mutations respond to EGFR-TKIs to some extent,10,11 the clinical effectiveness of EGFR-TKIs in non-small cell lung cancer (NSCLC) patients with these uncommon mutations remains unclear.

Retrospective studies on first-generation EGFR-TKIs gefitinib and erlotinib have shown variable responses in NSCLC patients with uncommon mutations.12–15 In contrast, second-generation EGFR-TKI afatinib has been reported to elicit a favorable response in patients with uncommon EGFR mutations, according to the LUX-Lung clinical trials (a single group phase 2 trial [LUX-Lung 2] and randomized phase 3 trials [LUX-Lung 3 and 6]).16 However, the effectiveness of EGFR-TKIs in clinical practice for NSCLC patients harboring uncommon EGFR mutations remain controversial because of the lack of cohesive reports.

In this study, we investigated the clinical features of NSCLC patients with uncommon EGFR mutations (including single or compound mutations) treated with first- and second-generation EGFR-TKIs. Furthermore, we focused on all clinical courses for this cohort, including cytotoxic chemotherapy (CCT) and immune checkpoint inhibitors (ICIs).

Methods
Patients and data collection
We performed a retrospective survey of a consecutive database of locally advanced or metastatic NSCLC (pathologically or cytologically proven) patients with EGFR mutations at five participating institutions. Patients with NSCLC harboring EGFR mutations were enrolled in the study if: (i) they were on any systemic therapy on 25 May 2016 and anticipated a new therapy after disease progression (PD); or (ii) they started first-line therapy after 25 May 2016. Data from NSCLC patients with uncommon EGFR mutations (including single or complex mutations) were collected by an independent site-monitoring organization (EP-SOGO Co., Ltd.) and were subsequently analyzed. Patient accrual ended on 31 October 2018 and the data cutoff time was 31 October 2019. The study protocol (UMIN000028989) was approved by the ethics committee of the participating institutions.

Clinical assessments
The antitumor response to treatment was assessed on the basis of the Response Evaluation Criteria in Solid Tumors (version 1.1) using computed tomography (CT). For cases without CT examination but wherein clinical symptoms or chest X-ray suggested PD, PD onset was defined as the date when the attending physician clinically evaluated PD. Progression-free survival (PFS) was defined as the interval from the start of any systemic therapy to patient death or PD detection. Overall survival (OS) was defined as the period from the start of any systemic therapy to the date when the patient died or was last known to be alive. Duration of treatment (DOT) was defined as the interval from the start of each treatment to the date when the treatment was discontinued or was last known to be given.

Statistical analysis
PFS, OS, and DOT curves were estimated using the Kaplan–Meier method. The log-rank test was used to compare survival between groups. Statistical analyses were performed using SPSS software version 22.0 (IBM, Chicago, IL, USA).

Results
Patient characteristics
A total of 23 of the 542 patients whose data were collected had uncommon EGFR mutations. Of them, 22 received EGFR-TKIs between May 2016 and October 2019. Patient demographics are summarized in Table 1. All patients were diagnosed with adenocarcinoma. The median age was 72.5 (range, 54–86) years. A total of 13 patients (56.5%) were
female, and 10 patients (43.5%) were never-smokers; 18 patients were treated with EGFR-TKIs as first-line therapy, and four patients received EGFR-TKIs as second- or late-line therapy. A total of 10 patients were treated with first-generation (gefitinib = 6, erlotinib = 4) and 12 were treated with second-generation (afatinib) EGFR-TKIs.

**Response per EGFR-TKI generation**

There were 10 patients who received first-generation EGFR-TKI (gefitinib or erlotinib) therapy (first-line = 8, second- or late-line = 2). The response to this therapy was favorable (RR = 60%, DCR = 90%). In contrast, 12 patients received second-generation EGFR-TKI (afatinib) therapy (first-line = 10, second- or late-line = 2), with likewise favorable response (RR = 58.3%, DCR = 83.3%).

There was no significant difference in PFS between the first-generation (n = 10, median PFS = 14.0 months [95% CI: 3.2–25.8]) and second-generation (n = 12, median PFS = 7.3 months [95% CI: 0–22.5]) EGFR-TKIs (Fig 1c). Nevertheless, numerous patients have continued receiving EGFR-TKI therapies, especially those in the afatinib cohort (Fig 2a); hence, the data presented may be premature.

**Response to EGFR-TKIs per mutation subcategory**

The overall response rate (RR) and disease control rate (DCR) of NSCLC patients with uncommon *EGFR* mutations who received first EGFR-TKI therapy was 59.1% and 81.8%, respectively (Table 2). A total of 13 patients exhibited partial response (PR). Within the single mutation subcategory, nine out of 13 patients with G719X mutation (RR = 69.2%, DCR = 84.6%) and two out of four patients with L861Q mutation (RR = 50.0%, DCR = 100%) exhibited PR. In contrast, within the compound mutation subcategory, two out of four patients exhibited PR (RR = 50.0%, DCR = 75.0%).

The median PFS following first EGFR-TKI therapy was 14.0 months (95% confidence interval [CI]: 3.2–25.8) in all patients with uncommon mutations (Fig 1a). No significant difference in PFS was observed between the single and compound mutation subcategories. Nevertheless, the PFS of patients with G719X mutation was favorable (n = 13, median PFS = 32.9 months [95% CI: 3.1–62.6]), compared to those with L861Q (n = 4, median PFS = 6.4 months [95% CI: 0–14.1]) or compound (n = 4, median PFS = 7.3 months [95% CI: 0–18.9]) mutations (Fig 1b).

**Cumulative DOT and OS in patients with uncommon mutations**

The median cumulative DOT for EGFR-TKI therapy was 30.4 months (n = 22, 95% CI: 8.6–52.1). This was longer than that of CCT (n = 11, median DOT = 10.7 months [95% CI: 3.1–62.6]) or ICI (n = 9, median DOT = 6.6 months [95% CI: 0–17.6]) (Fig 2a,b). Furthermore, the median OS from the start of any systemic treatment (except for pre- and postoperative chemotherapy or chemoradiotherapy) was 79.9 months (95% CI: 5.4–154.3) (Fig 2c). Nevertheless, numerous patients have continued to receive therapies; hence, the data presented may be premature.

**Discussion**

This study demonstrated that both first- and second-generation EGFR-TKIs elicit clinical responses in NSCLC patients with uncommon mutations. According to previous reports, first-generation EGFR-TKIs were less effective in NSCLC patients with uncommon mutations than in those with common mutations.12–15 Furthermore, Chiu *et al.*
Figure 1 Kaplan–Meier curves for progression-free survival (PFS) following first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in patients with uncommon EGFR mutations. (a) PFS of all patients with uncommon EGFR mutations (N = 22). (b) PFS of patients with G719X, L861Q, and compound mutations [G719X (N = 13), L861Q (N = 4), Compound mutation (N = 4)]. (c) PFS of patients harboring uncommon EGFR mutations treated with first- and second-generation EGFR-TKIs [First-generation EGFR-TKI (N = 10), Second-generation EGFR-TKI (N = 12)].
reported that first-generation EGFR-TKI treatment efficacy was similar among patients with uncommon single mutations (G719X: median PFS = 6.3 months, L861Q: median PFS = 8.1 months). In contrast, afatinib—an irreversible second-generation EGFR-TKI—elicted better responses in patients with G719X mutation than in those with L861Q.

Figure 2 The entire clinical course and overall survival (OS) in patients with uncommon mutations. (a) The treatment durations of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), immune checkpoint inhibitor (ICI), and cytotoxic chemotherapy (CCT) were indicated in each patient harboring uncommon EGFR mutations (First-generation EGFR-TKI, Second-generation EGFR-TKI, Third-generation EGFR-TKI, ICI, CCT, Death, Ongoing treatment). (b) Kaplan-Meier curves for cumulative duration of treatment EGFR-TKI (N = 22), ICI (N = 9), CCT (N = 11); and OS (c) in patients with uncommon EGFR mutations (N = 23).
Thoracic Cancer 12 (2021) 90-96 © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Table 2  Response to EGFR-TKIs per mutation subcategory

| Mutation Type | Exon 20 Insertion (N = 1) | G719X (N = 13) | L861Q (N = 4) | Compound Mutation (N = 4) | All (N = 22) |
|---------------|---------------------------|----------------|--------------|---------------------------|-------------|
| CR            | 0                         | 0              | 0            | 0                         | 0           |
| PR            | 0                         | 9              | 2            | 2                         | 13          |
| SD            | 0                         | 2              | 2            | 1                         | 5           |
| PD            | 1                         | 0              | 0            | 1                         | 2           |
| NE            | 0                         | 7              | 0            | 0                         | 2           |
| RR (%)        | 0                         | 69.2           | 50.0         | 50.0                      | 59.1        |
| DCR (%)       | 0                         | 84.6           | 100.0        | 75.0                      | 81.8        |

CR, complete response; DCR, disease control rate; NE, not evaluated; PD, progressive disease; PR, partial response; RR, response rate; SD, stable disease.

Our results are consistent with those of previous reports in that EGFR-TKIs elicited only moderate activity in patients with L861Q mutation. By contrast, EGFR-TKIs appear to have elicited favorable activity in patients with G719X mutation (Fig 2a,b); however, this may be premature because numerous patients have continued receiving EGFR-TKI therapy, especially in the afatinib cohort. Afatinib is currently in phase III testing to investigate whether this second-generation EGFR-TKI can improve clinical outcomes for NSCLC patients with uncommon mutations compared with platinum doublet chemotherapy. Moreover, a recent report indicated that osimertinib, a third-generation EGFR-TKI, also elicited favorable activity in NSCLC patients with uncommon mutations. In our study, only two patients were treated with osimertinib as late-line therapy (Fig 2a); thus, its effect in this cohort was unclear.

The clinical effectiveness of CCT or ICI in patients with uncommon EGFR mutations also remains unclear. We therefore surveyed all clinical courses as well as OS in this cohort. Watanabe et al. reported that in a cohort of patients receiving carboplatin plus platinaxel therapy, the OS of patients with uncommon EGFR mutations was similar to those of patients with common mutations; in another patient cohort (receiving gefitinib therapy) the OS of those with uncommon mutations was shorter than those with common mutations. Moreover, several reports showed that ICIs conferred less sensitivity in EGFR-mutated NSCLC. However, patients with uncommon EGFR mutations had better response and long-term survival. Yamada et al. showed that patients with uncommon EGFR mutations had significantly better PFS (median PFS = 8.5 months) compared to those with common mutations (median PFS = 1.7 months). In our study, ICIs elicited moderate responses in patients with uncommon EGFR mutations. Moreover, several patients did not exhibit PD during ICI therapy. Our results indicate that in addition to EGFR-TKIs, CCT and ICIs contribute to long-term disease control in patients with uncommon mutations.

This study has several limitations. First, the sample size was small because of the rare nature of the mutation being studied. Previous studies also had sample sizes similar to our own. Moreover, despite this limitation, we believe that our results are relevant because we focused on specific patient characteristics, mutation status, and the entire clinical course. Second, our study was retrospective and only included Japanese patients. There may be various patient condition biases when each treatment was initiated.

In summary, both first- and second-generation EGFR-TKIs elicit favorable responses in NSCLC patients with uncommon EGFR mutations. Further studies are warranted to develop the optimal treatment strategy in this rare cohort.

Acknowledgment
We thank all patients, including their families, for their participation in this study.

Disclosures
This research was supported by AstraZeneca. M Kanazu reports speaker’s fees from AstraZeneca and Chugai. M Mori reports speaker’s fees from AstraZeneca, Chugai, and Boehringer Ingelheim. K Nishino reports personal fees from AstraZeneca, Chugai, Pfizer, and Boehringer Ingelheim and grants from Boehringer Ingelheim. I Nagatomo reports personal fees and grants from AstraZeneca and Chugai. H Suzuki reports personal fees from AstraZeneca and Chugai. T Hirashima reports speaker’s fees from AstraZeneca, Chugai, and Pfizer and research funds from AstraZeneca and Chugai. T Kumagai reports speaker’s fees and research funds from AstraZeneca, Chugai, Pfizer, and Boehringer Ingelheim. F Imamura reports honoraria from AstraZeneca, Chugai, Pfizer, and Boehringer Ingelheim and research funds from AstraZeneca. M Kimura, T Shiroyama, S Ihara and K Komuta report no financial interest or conflict of interest. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
References

1 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–57.
2 Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380–8.
3 Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–8.
4 Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–42.
5 Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239–46.
6 Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339–46.
7 Paris AG, Voutsina A, Kalikaki A et al. ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 2007; 97: 1560–6.
8 Beau-Faller M, Prim N, Ruppert AM et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: A multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 2014; 25: 126–31.
9 Shi Y, Au JS, Thongprasert S et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9: 154–62.
10 Chen YR, Fu YN, Lin CH et al. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 2006; 25: 1205–15.
11 Kancha RK, von Bubnoff N, Peschel C, Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009; 15: 460–7.
12 Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011; 17: 3812–21.
13 Watanabe S, Minegishi Y, Yoshizawa H et al. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol 2014; 9: 189–94.
14 Chiu CH, Yang CT, Shih JY et al. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol 2015; 10: 793–9.
15 Otsuka T, Mori M, Yano Y et al. Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: Results from a multicenter retrospective study (HANSHIN oncology group 0212). Anticancer Res 2015; 35: 3885–91.
16 Yang JC, Sequist LV, Geater SL et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-lung 2, LUX-lung 3, and LUX-lung 6. Lancet Oncol 2015; 16: 830–8.
17 Shen YC, Tseng GC, Tu CY et al. Comparing the effects of afatinib with gefitinib or erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Lung Cancer 2017; 110: 56–62.
18 Yang JC, Schuler M, Popat S et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: A database of 693 cases. J Thorac Oncol 2020; 15: 803–15.
19 Miura S, Yamanaka T, Kato T et al. Treatment rationale and design of a phase III study of afatinib or chemotherapy in patients with non-small-cell lung cancer harboring sensitizing uncommon epidermal growth factor receptor mutations (ACHILLES/TORG1834). Clin Lung Cancer 2020; 21: e592–e596.
20 Cho JH, Lim SH, An HJ et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol 2020; 38: 488–95.
21 Gainor JF, Shaw AT, Sequist LV et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis. Clin Cancer Res 2016; 22: 4585–93.
22 Lee CK, Man J, Lord S et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis. J Thorac Oncol 2017; 12: 403–7.
23 Gettinger S, Horn L, Jackman D et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study. J Clin Oncol 2018; 36: 1675–84.
24 Yoshida H, Kim YH, Ozasa H et al. Nivolumab in non-small-cell lung cancer with EGFR mutation. Ann Oncol 2018; 29: 777–8.
25 Yamada T, Hirai S, Katayama Y et al. Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. Cancer Med 2019; 8: 1521–9.